Abstract
The expression of activated mutants of M-Ras (G22V or Q71L), but not wild-type M-Ras, in a murine mammary epithelial cell line, scp2, resulted in epithelial–mesenchymal transition (EMT) and oncogenic transformation. Cells expressing constitutively active M-Ras continued to grow in the absence of serum and exhibited a loss of the epithelial markers cytokeratin, E-cadherin and β-catenin, together with a gain of the mesenchymal marker vimentin, a loss of contact inhibition in monolayer growth and a gain of the capacity for anchorage-independent growth. Moreover, unlike the parental cells, they failed to form differentiated mammospheres on Matrigel and instead formed branched networks of cells that grew and invaded the Matrigel. The expression of activated p21 Ras (G12V H-Ras or Q61K N-Ras) also resulted in EMT and tumorigenesis, although there was evidence that expression of higher levels was toxic. Tumors derived from scp2 cells expressing activated M-Ras exhibited activation of Akt and of ERK. The levels of expression of Q71L M-Ras and G12V H-Ras required for tumorigenesis were comparable, although higher levels of the weaker G22V M-Ras mutant were selected for in vivo. These data indicate that the expression of activated mutants of M-Ras was sufficient for oncogenic transformation of a murine mammary epithelial cell line.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barker KT and Crompton MR . (1998). Br. J. Cancer, 78, 296–300.
Boon K, Osorio EC, Greenhut SF, Schaefer CF, Shoemaker J, Polyak K, Morin PJ, Buetow KH, Strausberg RL, De Souza SJ and Riggins GJ . (2002). Proc. Natl. Acad. Sci. USA, 99, 11287–11292.
Bos JL . (1988). Mutat. Res., 195, 255–271.
Bos JL . (1989). (Published erratum appears in Cancer Res. (1990) Feb 15; 50(4): 1352). Cancer Res., 49, 4682–4689.
Chan AM, Miki T, Meyers KA and Aaronson SA . (1994). Proc. Natl. Acad. Sci. USA, 91, 7558–7562.
Clark GJ, Kinch MS, Gilmer TM, Burridge K and Der CJ . (1996). Oncogene, 12, 169–176.
Cox AD, Brtva TR, Lowe DG and Der CJ . (1994). Oncogene, 9, 3281–3288.
Crissman HA, Darzynkiewicz Z, Tobey RA and Steinkamp JA . (1985). Science, 228, 1321–1324.
Danielson KG, Oborn CJ, Durban EM, Butel JS and Medina D . (1984). Proc. Natl. Acad. Sci. USA, 81, 3756–3760.
Desprez P, Roskelley C, Campisi J and Bissell MJ . (1993). Mol. Cell. Differ., 1, 99–110.
Ehrhardt A, Ehrhardt G, Guo X and Schrader J . (2002). Exp. Hematol., 30, 1089.
Ehrhardt GR, Korherr C, Wieler JS, Knaus M and Schrader JW . (2001). Oncogene, 20, 188–197.
Ehrhardt GR, Leslie KB, Lee F, Wieler JS and Schrader JW . (1999). Blood, 94, 2433–2444.
Fanton CP, McMahon M and Pieper RO . (2001). J. Biol. Chem., 276, 18871–18877.
Gao X, Satoh T, Liao Y, Song C, Hu CD, Kariya Ki K and Kataoka T . (2001). J. Biol. Chem., 276, 42219–42225.
Grill B and Schrader JW . (2002). Blood, 100, 3183–3192.
Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ and Counter CM . (2002). Genes Dev., 16, 2045–2057.
Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H and Grunert S . (2002a). J. Cell. Biol., 156, 299–314.
Janda E, Litos G, Grunert S, Downward J and Beug H . (2002b). Oncogene, 21, 5148–5159.
Kimmelman A, Tolkacheva T, Lorenzi MV, Osada M and Chan AM . (1997). Oncogene, 15, 2675–2685.
Kimmelman AC, Osada M and Chan AM . (2000). Oncogene, 19, 2014–2022.
Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z and Bissell MJ . (1997). J. Biol. Chem., 272, 5007–5015.
Louahed J, Grasso L, De Smet C, Van Roost E, Wildmann C, Nicolaides NC, Levitt RC and Renauld JC . (1999). Blood, 94, 1701–1710.
Lowe DG, Capon DJ, Delwart E, Sakaguchi AY, Naylor SL and Goeddel DV . (1987). Cell, 48, 137–146.
Macmanus MP, Elder GE, Abram WP and Bridges JM . (1990). Exp. Hematol., 18, 848–852.
Matsumoto K, Asano T and Endo T . (1997). Oncogene, 15, 2409–2417.
Miyakis S, Sourvinos G and Spandidos DA . (1998). Biochem. Biophys. Res. Commun., 251, 609–612.
Naviaux RK, Costanzi E, Haas M and Verma IM . (1996). J. Virol., 70, 5701–5705.
Noda M . (1993). Biochim. Biophys. Acta, 1155, 97–109.
Ohba Y, Mochizuki N, Yamashita S, Chan AM, Schrader JW, Hattori S, Nagashima K and Matsuda M . (2000). J. Biol. Chem., 275, 20020–20026.
Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D . (2000). Nature, 406, 747–752.
Pritchard C and McMahon M . (1997). Nat. Genet., 16, 214–215.
Pruitt K, Pruitt WM, Bilter GK, Westwick JK and Der CJ . (2002). J. Biol. Chem., 277, 31808–31817.
Quilliam LA, Castro AF, Rogers-Graham KS, Martin CB, Der CJ and Bi C . (1999). J. Biol. Chem., 274, 23850–23857.
Quilliam LA, Rebhun JF, Zong H and Castro AF . (2001). Methods Enzymol., 333, 187–202.
Rebhun JF, Castro AF and Quilliam LA . (2000). J. Biol. Chem., 275, 34901–34908.
Roskelley CD, Wu C and Somasiri AM . (2000). Methods Mol. Biol., 136, 27–38.
Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M and Dent P . (1998). Biochem. J., 330 (Part 3), 1451–1460.
Tremblay PJ, Pothier F, Hoang T, Tremblay G, Brownstein S, Liszauer A and Jolicoeur P . (1989). Mol. Cell. Biol., 9, 854–859.
Urano T, Emkey R and Feig LA . (1996). EMBO J., 15, 810–816.
Woods D, Parry D, Cherwinski H, Bosch E, Lees E and McMahon M . (1997). Mol. Cell. Biol., 17, 5598–5611.
Acknowledgements
We thank Dr Goetz Ehrhardt for critical discussions and Andy Johnson for assistance with FACS analysis. This work was supported by grants from the Canadian Breast Cancer Research Initiative and the Canadian Institutes of Health Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Rights and permissions
About this article
Cite this article
Ward, K., Zhang, KX., Somasiri, A. et al. Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial–mesenchymal transition and tumorigenesis. Oncogene 23, 1187–1196 (2004). https://doi.org/10.1038/sj.onc.1207226
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207226
Keywords
This article is cited by
-
RNA-sequencing reveals long-term effects of silver nanoparticles on human lung cells
Scientific Reports (2018)
-
Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis
BMC Cancer (2010)
-
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms
BMC Genomics (2006)
-
Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells
Oncogene (2006)
-
Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras
Oncogene (2005)